JSP191

REDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today…

JSP191 is currently being evaluated in four ongoing clinical studies in allogeneic hematopoietic stem cell transplant in patients with Acute Myeloid Leukemia (AML) / Myelodysplastic…

JSP191 is well tolerated with no treatment-related severe adverse events in 24 patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in Ph1b dose expansion study24 of…

JSP191 is well tolerated with no treatment-related severe adverse events in 17 subjects with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in Ph1b dose expansion study17 of…

JSP191 is well tolerated with no treatment-related adverse events in dose-escalation studySingle-agent conditioning with JSP191 is associated with engraftment, immune reconstitution, and…